Personal Care Products and Human Health provides background, historical context and the latest research results on personal care products (PCPs) and their impact on human health and the environment. Sections provide an overview of the functions and mechanisms of action of components of personal care products, discuss environmental toxicology, outline the problems of contamination of water systems from increasing use of personal care products and the resulting toxicities to aquatic wildlife, and offer chapters written by specialists on different aspects of concern for the effects of excessive personal care product usage on human health. This is a comprehensive reference for toxicologists, environment scientists and those interested in learning about the science behind personal care products and current concerns for environmental and human health.

Polymeric Nanoparticles as Promising Tool for Anti-cancer Therapeutics provides an understanding of polymeric compounds and their use in cancer therapies. The book begins by giving an overview of the current status, future challenges and potential utilization of polymeric nanoparticles. It then covers specific polymeric nanoparticles through contributions from world-renowned experts and researchers. Chapters examine specific polymeric nanoparticles, their development as potential targeted delivery systems, and cancer characteristics that can be targeted for therapy development. The book synthesizes current research trends in the field, thus enhancing existing knowledge of nanomedicine, drug delivery and therapeutic intervention strategies in human cancers. Users will find this to be an ideal reference for research scientists and those in the pharmaceutical and medical fields who are working to develop novel cancer therapies using nanoparticle-based delivery systems.

Some of the more recent efforts in tuberculosis (TB) and trypanosomiasis drug discovery from both Product Development Partnerships (PDPs) and academia are highlighted in this this volume. Drug discovery approaches include both target- and phenotypic whole cell screening- approaches. Regarding the latter, mechanism of action studies through target identification are also illustrated.

Herbal, Bio-nutrient and Drug Titration According to Disease Stages in Integrative Cardiovascular Chinese Medicine, the first volume in the Integrative Cardiovascular Chinese Medicine series, provides a comprehensive guide to improving outcomes with cardiovascular medicine therapy options. Coverage includes the three types of medicines used in disease stage treatment, Chinese medicine, nutritional supplements and pharmaceutical drugs. All sections are organized according to drug class in western medicine and chapters in each section are organized according to disease stage, providing ease in navigation and reference within the book. This important reference will aid cardiovascular researchers in the study of integrative Chinese and western medicine as well as provide a clear, structured base to guide clinical practice and encourage collaboration between Chinese and Western medicine practitioners.

Neuropsychotherapeutics, Volume 86, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field, with this updated edition including sections on Pharmacotherapy of psychiatric disorders, Allosteric mechanisms for neuropsychopharmacology, Lipid rafts, Rapid-acting antidepressants, mGlu2/3 receptor antagonists, Nitric oxide: antidepressant mechanisms and inflammation, Anxiety disorders, mGlu receptors and schizophrenia, mAChR ligands for schizophrenia and addiction, PDE10 inhibitors, Obsessive-compulsive disorder, Addiction disorders (including eating), Dopamine D1 PAMs as a New Mode for Treatment of Neuropsychiatric Disorders, and more.

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more.

Pharmacology of Restless Legs Syndrome (RLS), Volume 84, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field on essential topics, with this volume presenting chapters on Targeting the adenosinergic system in Restless Legs Syndrome, Assessing iron uptake mechanisms in the brain: impact of gender and genotype, Pharmacological treatments of RLS in augmentation, C. elegans and its applicability to studies on RLS, The neurophysiology of hyperarousal in RLS: hints for a role of glutamate/GABA, Treatment management and options in RLS patients, Pharmacological responsiveness of Periodic Legs Movements during Sleep, and more.

The high failure rate in the pharmaceutical industry has positioned biomarkers and personalized medicine in the frontline, as possible solutions. If executed right, biomarkers and companion diagnostics (CDx) can potentially help the drug industry enhance the probability of success, accelerate the time to market, and, more importantly, benefit patients by supporting accurate diagnosis and selection of the most effective and least toxic therapies. This book aims to examine the challenges and limitations in biomarkers and laboratory tests. It also offers advice on best practices to ensure proper application of biomarkers and bridges the gap between diagnostic business development claims and real-life deliverables. The book covers biomarkers for different purposes, provides examples from different technologies, which includes standard-of-care approved assays as well as for-investigational-use and for-research-use-only assays. It also includes new data for biomarkers in different therapeutic indications and offers case studies and practical examples. This book serves as a reference to drug developers, IVD providers, clinical labs, healthcare givers, academicians, and researchers for best practices to help increase the probability of success in drug development and improve patient management.